Prevencio
Prevencio is dedicated to revolutionizing cardiovascular care through affordable, accessible, and highly accurate AI-driven blood tests. Their innovative tests employ machine learning algorithms to analyze multiple proteins and clinical variables, providing personalized risk assessments for heart attack, stroke, and other cardiovascular events. With a focus on prevention and early detection, Prevencio aims to improve patient outcomes and reduce healthcare costs by enabling proactive management of heart health.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Prognostic short-term cardiovascular risk blood test
A blood-based prognostic assay assessing multiple protein biomarkers and producing a machine-learning-derived risk score for short-term (approximately 1–2 year) risk of major adverse cardiovascular events.
Diagnostic blood test for obstructive coronary disease
A diagnostic blood assay combining multiple protein biomarkers and clinical variables in a predictive algorithm to estimate the probability of obstructive coronary artery disease.
Specialty indication biomarker panels
A set of blood-based biomarker panels optimized for specific indications including peripheral artery disease, acute kidney injury risk, aortic stenosis screening, amputation risk stratification, and pediatric inflammatory disease diagnosis.
Prognostic short-term cardiovascular risk blood test
A blood-based prognostic assay assessing multiple protein biomarkers and producing a machine-learning-derived risk score for short-term (approximately 1–2 year) risk of major adverse cardiovascular events.
Diagnostic blood test for obstructive coronary disease
A diagnostic blood assay combining multiple protein biomarkers and clinical variables in a predictive algorithm to estimate the probability of obstructive coronary artery disease.
Specialty indication biomarker panels
A set of blood-based biomarker panels optimized for specific indications including peripheral artery disease, acute kidney injury risk, aortic stenosis screening, amputation risk stratification, and pediatric inflammatory disease diagnosis.
Services
Assay of multi-protein blood panels in a central laboratory with algorithmic processing to produce individualized diagnostic or prognostic risk scores; samples accepted from clinics, draw centers, or patient home collection.
Design and execution of collaborative studies with academic centers and hospitals for external validation, subgroup analyses, and outcomes research to support clinical utility and publication.
Provision of biomarker testing, serial measurements, and risk scoring for Phase IV studies and early-stage drug/device development to evaluate treatment effects, safety, or to identify trial populations.
Web-based ordering and result-tracking portal for clinicians and laboratories, plus provider-facing interpretation materials to support result interpretation and clinical decision-making.
Assay of multi-protein blood panels in a central laboratory with algorithmic processing to produce individualized diagnostic or prognostic risk scores; samples accepted from clinics, draw centers, or patient home collection.
Design and execution of collaborative studies with academic centers and hospitals for external validation, subgroup analyses, and outcomes research to support clinical utility and publication.
Provision of biomarker testing, serial measurements, and risk scoring for Phase IV studies and early-stage drug/device development to evaluate treatment effects, safety, or to identify trial populations.
Web-based ordering and result-tracking portal for clinicians and laboratories, plus provider-facing interpretation materials to support result interpretation and clinical decision-making.
Expertise Areas
- Proteomic biomarker panel development
- Machine-learning-driven clinical risk modeling
- Clinical validation and outcomes research
- Centralized laboratory testing for LDTs
Key Technologies
- Supervised machine learning for clinical models
- Multiplex protein immunoassays and targeted proteomics
- Algorithmic risk scoring
- Cloud-based laboratory ordering and results portal
News & Updates
Prevencio was recognized as a top trusted company in heart care for 2022, highlighting their innovative AI-driven diagnostics.
A study presented at the American College of Cardiology Scientific Session showed that Prevencio's biomarker panel effectively predicts cardiovascular risks in diabetic patients.
Prevencio's AI-driven blood tests analyze multiple proteins and clinical variables to assess cardiovascular risk, enabling early detection and prevention.
Proprietary CPT Billing Codes for HART Tests
HART CVE™ and HART CADhs™ received proprietary CPT billing codes in 2022, facilitating insurance reimbursement.
Clinical Validation of HART Tests
Prevencio's HART tests are backed by over 32 peer-reviewed publications and clinical studies demonstrating high accuracy and predictive value.
Prevencio was recognized as a top trusted company in heart care for 2022, highlighting their innovative AI-driven diagnostics.
A study presented at the American College of Cardiology Scientific Session showed that Prevencio's biomarker panel effectively predicts cardiovascular risks in diabetic patients.
Prevencio's AI-driven blood tests analyze multiple proteins and clinical variables to assess cardiovascular risk, enabling early detection and prevention.
Proprietary CPT Billing Codes for HART Tests
HART CVE™ and HART CADhs™ received proprietary CPT billing codes in 2022, facilitating insurance reimbursement.
Clinical Validation of HART Tests
Prevencio's HART tests are backed by over 32 peer-reviewed publications and clinical studies demonstrating high accuracy and predictive value.